【佳學(xué)基因檢測】胰島素樣生長因子 (IGF) 軸在非小細(xì)胞肺癌中的不同作用

基因檢測多少錢一次1萬八解剖

與專家交流發(fā)現(xiàn)《Curr Pharm Des》在.?2022;28(25):2052-2064.發(fā)表了一篇題目為《胰島素樣生長因子 (IGF) 軸在非小細(xì)胞肺癌中的不同作用》腫瘤靶向藥物治療基因檢測臨床研究文章。該研究由Xiongye Xu,?Yanli Qiu,?Simin Chen,?Shuaishuai Wang,?Ruifu Yang,?Baomo Liu,?Yufei Li,?Jiating Deng,?Yan Su,?Ziying Lin,?Jincui Gu,?Shaoli Li,?Lixia Huang,?Yanbin Zhou?等完成。促進了腫瘤的正確治療與個性化用藥的發(fā)展，進一步強調(diào)了基因信息檢測與分析的重要性。

腫瘤靶向藥物及正確治療臨床研究內(nèi)容關(guān)鍵詞：

IGF-1, IGF-1R, IGF-2, IGF結(jié)合蛋白,非小細(xì)胞肺癌,癌癥治療耐藥性,信令,治療

腫瘤靶向治療基因檢測臨床應(yīng)用結(jié)果

非小細(xì)胞肺癌（NSCLC）仍然是賊致命的惡性腫瘤之一，在全球范圍內(nèi)具有高發(fā)病率和死亡率。由 IGF-1、IGF-2、相關(guān)受體 (IGF-1R、-2R) 和高親和力結(jié)合蛋白 (IGFBP 1-6) 組成的胰島素樣生長因子 (IGF) 軸與促進胎兒發(fā)育有關(guān)發(fā)育、組織生長和新陳代謝。新興研究還確定了 IGF 軸在 NSCLC 中的作用，包括癌癥生長、侵襲和轉(zhuǎn)移。 IGE-1 和 IGF-2 的上調(diào)、IGF-1R 的過表達(dá)以及參與 PI-3K/Akt 和 MAPK 通路的下游信號分子的失調(diào)共同增加了 NSCLC 中癌癥生長和遷移的風(fēng)險。在遺傳水平上，一些非編碼RNA可以通過IGF信號通路影響腫瘤細(xì)胞的增殖和分化。對一些有希望的藥物的耐藥性可能部分歸因于 IGF 軸。已經(jīng)評估了針對 IGF 軸的治療策略，其中一些已顯示出有希望的療效。在這篇綜述中，我們總結(jié)了 IGF 軸在 NSCLC 中的生物學(xué)作用，包括相關(guān)成分的表達(dá)和預(yù)后意義、非編碼 RNA 調(diào)控、參與耐藥性和治療應(yīng)用。這篇綜述提供了對NSCLC的全面認(rèn)識，并為未來的研究提供了深刻的思路。關(guān)鍵詞：IGF-1； IGF-1R； IGF-2; IGF結(jié)合蛋白；非小細(xì)胞肺癌；癌癥治療耐藥性；信令；治療。

腫瘤發(fā)生與反復(fù)轉(zhuǎn)移國際數(shù)據(jù)庫描述：

Non-small cell lung cancer (NSCLC) remains one of the deadliest malignant diseases, with high incidence and mortality worldwide. The insulin-like growth factor (IGF) axis, consisting of IGF-1, IGF-2, related receptors (IGF-1R, -2R), and high-affinity binding proteins (IGFBP 1-6), is associated with promoting fetal development, tissue growth, and metabolism. Emerging studies have also identified the role of the IGF axis in NSCLC, including cancer growth, invasion, and metastasis. Upregulation of IGE-1 and IGF-2, overexpression of IGF-1R, and dysregulation of downstream signaling molecules involved in the PI-3K/Akt and MAPK pathways jointly increase the risk of cancer growth and migration in NSCLC. At the genetic level, some noncoding RNAs could influence the proliferation and differentiation of tumor cells through the IGF signaling pathway. The resistance to some promising drugs might be partially attributed to the IGF axis. Therapeutic strategies targeting the IGF axis have been evaluated, and some have shown promising efficacy. In this review, we summarize the biological roles of the IGF axis in NSCLC, including the expression and prognostic significance of the related components, noncoding RNA regulation, involvement in drug resistance, and therapeutic application. This review offers a comprehensive understanding of NSCLC and provides insightful ideas for future research.Keywords:?IGF-1; IGF-1R; IGF-2; IGF-binding proteins; NSCLC; cancer therapeutic resistance; signaling; treatment.